↓ Skip to main content

Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study

Overview of attention for article published in International Journal of Cardiology, August 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
65 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study
Published in
International Journal of Cardiology, August 2015
DOI 10.1016/j.ijcard.2015.07.080
Pubmed ID
Authors

Andrew M. Tonkin, Stefan Blankenberg, Adrienne Kirby, Tanja Zeller, David M. Colquhoun, Anne Funke-Kaiser, Wendy Hague, David Hunt, Anthony C. Keech, Paul Nestel, Ralph Stewart, David R. Sullivan, Peter L. Thompson, Malcolm West, Harvey D. White, John Simes, for the LIPID study investigators

Abstract

In patients with stable coronary heart disease (CHD), we aimed to assess 1. the prognostic power of biomarkers reflecting haemodynamics, micronecrosis, inflammation, coagulation, lipids, neurohumoral activity, and renal function; 2. whether changes in concentrations of these biomarkers over 12months affected subsequent CHD risk; and 3. whether pravastatin modified the change in biomarker concentrations and this influenced the risk of future events. In the LIPID study, 9014 patients were randomised to pravastatin 40mg or placebo 3-36months after an acute coronary syndrome. Eight biomarkers were measured at baseline (n=7863) and 12months later (n=6434). During a median of 6.0 (IQR 5.5-6.5) years follow-up, 1100 CHD-related deaths and nonfatal myocardial infarctions occurred, 694 after biomarker measurement at 12months. Baseline BNP, CRP, cystatin C, D-dimer, midregional pro-adrenomedullin, and sensitive troponin I predicted recurrent CHD events. In a multivariable model, sensitive troponin I, BNP, and cystatin C had the strongest associations with outcome (P<0.001 for trend). The strongest improvement in risk prediction was achieved by including sensitive troponin I (net reclassification improvement (NRI) 5.5%; P=0.003), BNP (4.3%; P=0.02), history of MI (NRI 7.0%; P<0.001). In landmark analyses, among biomarkers, changes to 12months in sensitive troponin I (HR 1.32 (1.03-1.70) for T3/T1), BNP (HR 1.37 (1.10-1.69) for Q4/Q1) and Lp-PLA2 (HR 1.52 (1.16-1.97)) improved CHD risk prediction. Baseline levels and changes in sensitive troponin I, and BNP may have the potential to guide the intensity of secondary prevention therapy.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Netherlands 1 2%
Unknown 63 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 15%
Student > Bachelor 9 14%
Student > Ph. D. Student 8 12%
Student > Master 8 12%
Student > Postgraduate 4 6%
Other 9 14%
Unknown 17 26%
Readers by discipline Count As %
Medicine and Dentistry 21 32%
Biochemistry, Genetics and Molecular Biology 4 6%
Nursing and Health Professions 3 5%
Agricultural and Biological Sciences 3 5%
Computer Science 2 3%
Other 9 14%
Unknown 23 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2022.
All research outputs
#8,262,107
of 25,374,647 outputs
Outputs from International Journal of Cardiology
#2,239
of 7,536 outputs
Outputs of similar age
#86,106
of 261,672 outputs
Outputs of similar age from International Journal of Cardiology
#43
of 161 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 7,536 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,672 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 161 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.